-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Achieving ''Next-Level'' Care in AML: Conversations on Targeted Platforms, Emerging Immunotherapies, and Implications for Precision Medicine

Sponsor: AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Diseases, Therapies
Friday, December 8, 2023: 3:00 PM-6:00 PM
Pacific Ballroom Salons 15-17 (Marriott Marquis San Diego Marina)
Chair:
Sergio A. Giralt, MD, FACP, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center
Disclosures:
Giralt: Amgen, Actinuum, Celgene/BMS, Kite Pharma, Janssen, Jazz Pharmaceuticals, Johnson & Johnson, Novartis, Spectrum Pharma, Takeda: Membership on an entity's Board of Directors or advisory committees; Amgen, Actinuum, Celgene/BMS, Omeros, Johnson & Johnson, Miltenyi, Takeda: Research Funding.
Speakers:
Tapan M. Kadia, MD, The University of Texas MD Anderson Cancer Center , Selina M Luger, MD, FRCPC, Perelman School of Medicine, Hospital of the University of Pennsylvania , Ghayas C. Issa, The University of Texas MD Anderson Cancer Center and Pinkal Desai, MD, MPH, EIPM Molecular Aging Institute, Weill Cornell Medicine
Disclosures:
Kadia: AbbVie, Amgen, Inc, Ascentage Pharma Group, Astellas Pharma Global Development, Astex, AstraZeneca, BMS, Celgene, Cellenkos Inc, Cyclacel, Delta-Fly Pharma, Inc, Genentech, Inc., Genfleet, Glycomimetics, Iterion, Janssen Research and Development: Research Funding; Servier: Consultancy; Cure: Speakers Bureau; Delta-Fly Pharma, Inc.: Research Funding; Cellenkos Inc.: Research Funding; Pinotb-Bio: Consultancy; BMS: Consultancy, Research Funding; Astex: Honoraria; Agios: Consultancy; Daiichi Sankyo, Genentech, Inc., Genzyme, Jazz Pharmaceuticals, Liberum, Novartis, Pfizer, PinotBio, Inc, Pulmotect, Inc, Sanofi-Aventis, Servier: Consultancy; Biologix, Cure, Hikma Pharmaceuticals: Speakers Bureau; Genzyme: Honoraria; Genentech: Consultancy, Research Funding; Cyclacel: Research Funding; Astellas Pharma Global Development: Research Funding; Ascentage Pharma Group: Research Funding; Amgen, Inc.: Research Funding; Jazz Pharmaceuticals, Pfizer, Pulmotect, Inc, Regeneron Pharmaceuticals, SELLAS Life Sciences Group: Research Funding; AstraZeneca: Research Funding; Celgene: Research Funding; GenFleet Therapeutics: Research Funding; Glycomimetics: Research Funding; Hikma Pharmaceuticals: Speakers Bureau; Iterion: Research Funding; Janssen Research and Development: Research Funding; Liberum: Consultancy; Novartis: Consultancy; Pfizer: Consultancy, Research Funding; Sanofi-Aventis: Consultancy; Regeneron Pharmaceuticals: Research Funding; Pulmotect, Inc.: Consultancy, Research Funding; SELLAS Life Sciences Group: Research Funding. Luger: Novartis: Consultancy; Marker Therapeutics: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Honoraria; Onconova: Research Funding; Astellas: Honoraria. Issa: Merck: Research Funding; NuProbe: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Syndax: Consultancy, Research Funding; Kura Oncology: Consultancy, Research Funding; Celgene: Research Funding; Astex: Research Funding; Abbvie: Consultancy; Cullinan Oncology: Research Funding. Desai: Janssen Pharmaceuticals: Current Employment; Servier: Consultancy, Other: Advisory role; Abbvie: Consultancy, Other: Advisory role; BMS: Consultancy, Other: Advisory role; Janssen Research & Development: Research Funding.
On Demand program will be available here December 13, 2023.

This CME activity is provided by Penn State College of Medicine and developed with our educational partners, PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Myeloid Leukemia.

This activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Astellas, Kura Oncology, Inc., and Syndax.

The modern management of acute myeloid leukemia (AML) has changed dramatically in recent years as innovative therapeutics, including FLT3, IDH, and BCL2 inhibitors; novel radioimmunoconjugate approaches; and newer epigenetic and targeted therapeutics (eg, menin inhibitors), have overturned the largely cytarabine-based chemotherapy standard of patient care. Strategic treatment planning is now more important than ever to ensure the safe delivery of different therapeutic drug classes.

To explore this “next level” of AML management, PeerView’s experts will use case-based Clinical Consult debates to illustrate how varying baseline patient features can alter treatment decisions and discuss strategies to leverage the fruits of new science to improve patient care. Each discussion will be supported by mini lectures covering current science and modern clinical decision-making strategies in a diversity of AML settings and patient presentations. Join us to achieve “next-level” care for your patients with AML!

See more of: Friday Satellite Symposia
<< Previous Application | Next Application >>